Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform.

MacKenna, Brian; Kennedy, Nicholas A; Mehrkar, Amir; Rowan, Anna; Galloway, James; Matthewman, Julian; Mansfield, Kathryn E; Bechman, Katie; Yates, Mark; Brown, Jeremy; +38 more... Schultze, Anna; Norton, Sam; Walker, Alex J; Morton, Caroline E; Harrison, David; Bhaskaran, Krishnan; Rentsch, Christopher T; Williamson, Elizabeth; Croker, Richard; Bacon, Seb; Hickman, George; Ward, Tom; Davy, Simon; Green, Amelia; Fisher, Louis; Hulme, William; Bates, Chris; Curtis, Helen J; Tazare, John; Eggo, Rosalind M; Evans, David; Inglesby, Peter; Cockburn, Jonathan; McDonald, Helen I; Tomlinson, Laurie A; Mathur, Rohini; Wong, Angel YS; Forbes, Harriet; Parry, John; Hester, Frank; Harper, Sam; Douglas, Ian J; Smeeth, Liam; Lees, Charlie W; Evans, Stephen JW; Goldacre, Ben; Smith, Catherine H; Langan, Sinéad M; (2022) Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. The Lancet Rheumatology, 4 (7). e490-e506. ISSN 2665-9913 DOI: https://doi.org/10.1016/S2665-9913(22)00098-4

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S2665-9913(22)00098-4

Abstract

Share

Download

Filename: MacKenna_etal_2022_Risk-of-severe-covid-19.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar